-
Mashup Score: 0lock - 7 month(s) ago
Medicare Drug Price Negotiation Program Patient-Focused Listening Sessions
Source: www.cms.govCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 0Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing - 10 month(s) ago
For the third time this year, Novartis has been rebuked by a U.K. trade group for misleading promotional efforts for its biggest-selling drug.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet-
Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing.. read the case reports here.. https://t.co/AWWUJ1IFCL #pharma #Entresto #heartfailure $NVS $NVO
-
-
Mashup Score: 0Tolerability and beneficial effects of sacubitril/valsartan on systemic right ventricular failure - PubMed - 12 month(s) ago
Treatment with sacubitril/valsartan was associated with a low rate of adverse effects in this adult sRV cohort. Persisting improvement in 6-minute walking test distance, NT-proBNP levels and echocardiographic parameters of sRV function was observed in an on-treatment analysis and showed no different …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
In an extension of previous work, #Entresto continues to show potential for #TGA pts with systemic RV. I've been switching my patients over the past year. Have you? @ShelbyKuttyMD @alexvdbruaene @AlexFrogoudaki @ACTION4HF https://t.co/68DBKfYadw
-
-
Mashup Score: 7Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study - PubMed - 1 year(s) ago
Our data showed that sacubitril/valsartan is well tolerated and is associated with systemic right ventricle remodeling and improved systolic function as well as improved clinical status, supporting its use in this complex population.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
I've been using #Entresto in my sysRV patients based on the Heart2021 study, here confirmation of potential benefit in surrogate endpoints!⬆️walk, QOL, sys function,⬇️ventricular volumes in 51pts x1y. @ShelbyKuttyMD @sasha_opo @ralogon @alexvdbruaene https://t.co/lOvrm429ZX
-
-
Mashup Score: 0Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction - 3 year(s) ago
This randomized clinical trial evaluates the use of sacubitril/valsartan therapy compared with valsartan alone in US patients with advanced chronic heart failure.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
"In patients with chronic advanced heart failure with a reduced ejection fraction, there was no statistically significant difference between sacubitril/valsartan and valsartan with respect to reducing NT-proBNP levels" https://t.co/5jiCjhwrjO @JAMACardio #Entresto #HFrEF https://t.co/WgYKqNlBaL
-
-
Mashup Score: 0This Week in Managed Care: February 19, 2021 - 3 year(s) ago
This week, the top managed care news included Entresto winning the first FDA nod in a hard-to-treat type of heart failure; President Joe Biden nominates a new CMS administrator; experts discuss the potential for Biden health reforms.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
This week, the top managed care news included #Entresto winning the first @US_FDA nod in a hard-to-treat type of #heartfailure; President Joe #Biden nominates a new @CMSGov administrator. Watch This Week in Managed Care: February 19, 2021! https://t.co/ECgygNblzo https://t.co/HXslIemSNG
-
-
Mashup Score: 1
Novartis’ drug, which combines sacubitril and valsartan, is the first to directly treat patients with heart failure with preserved ejection fraction.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#Entresto Wins First @US_FDA Nod in Hard-to-Treat Type of #HeartFailure https://t.co/spJr9tg6fv https://t.co/U1kZjUY9PH
-
-
Mashup Score: 11U.S. FDA approves expanded use of Novartis heart drug - 3 year(s) ago
The U.S. Food and Drug Administration has approved the expanded use of Novartis’ heart failure medicine Entresto, the Swiss drugmaker said on Tuesday, boosting the drug’s prospects to around $5 billion sales annually.
Source: U.S.Categories: Cardiologists, Latest HeadlinesTweet-
U.S. FDA approves expanded use of Novartis heart drug #Entresto to treat #HFpEF, a condition where the heart muscle squeezes normally, but cannot relax normally to fill up with blood https://t.co/AcDOkGzlvj
-
-
Mashup Score: 0
Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing patients with the condition.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#Entresto Is Top HFrEF Treatment Recommendation in Updated ACC Guidelines: https://t.co/78z87rkLmj @ACCinTouch https://t.co/mEWxqlP5zk
-
-
Mashup Score: 4FDA Panel Backs Entresto, Spironolactone for Broader HF Use - 3 year(s) ago
But committee stops short of advocating categorical approval for HFpEF
Source: www.medpagetoday.comCategories: Cardiologists, Latest HeadlinesTweet-
FDA Panel Backs #Entresto , #Spironolactone for Broader #HF Use https://t.co/HgUPnAdftA
-
Last chance to make your voice heard! If you use any of these medications, sign up to advocate for the lower prices you need: #Eliquis, #Jardiance, #Xarelto, #Januvia, #Farxiga, #Entresto, #Enbrel, #Imbruvica, #Stelara, #Fiasp, #NovoLog Learn more: https://t.co/vWjSB5TtV6